Welireg

Monitor for anemia, oxygen saturation prior to initiation and periodically during therapy. Withhold for hemoglobin <9g/dL or transfusion indicated until resolved; resume at reduced dose or permanently discontinue based on severity of anemia. For life-threatening anemia or when urgent intervention is indicated; withhold until resolved; resume at reduced dose or permanently discontinue. Consider withholding therapy for decreased oxygen saturation with exercise (eg, pulse oximeter <88% or P_aO₂ ≤55mmHg) until resolved, then resume at same or reduced dose. Withhold for decreased oxygen saturation at rest (eg, pulse oximeter <88% or P_aO₂ ≤55mmHg) or urgent intervention indicated until resolved; resume at reduced dose or discontinue based on severity of hypoxia. Permanently discontinue if life-threatening or recurrent symptomatic hypoxia occurs. Poor metabolizers (dual UGT2B17/CYP2C19): monitor closely. Severe renal impairment (eGFR 15–29mL/min/1.73m²). Moderate or severe hepatic impairment (total bilirubin >1.5×ULN and any AST). Embryo-fetal toxicity. Advise females of reproductive potential and males (w. female partners) to use effective non-hormonal contraception during and for 1 week after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 1 week after the last dose).

Monitor for anemia, oxygen saturation prior to initiation and periodically during therapy. Withhold for hemoglobin <9g/dL or transfusion indicated until resolved; resume at reduced dose or permanently discontinue based on severity of anemia. For life-threatening anemia or when urgent intervention is indicated; withhold until resolved; resume at reduced dose or permanently discontinue. Consider withholding therapy for decreased oxygen saturation with exercise (eg, pulse oximeter <88% or P_aO₂ ≤55mmHg) until resolved, then resume at same or reduced dose. Withhold for decreased oxygen saturation at rest (eg, pulse oximeter <88% or P_aO₂ ≤55mmHg) or urgent intervention indicated until resolved; resume at reduced dose or discontinue based on severity of hypoxia. Permanently discontinue if life-threatening or recurrent symptomatic hypoxia occurs. Poor metabolizers (dual UGT2B17/CYP2C19): monitor closely. Severe renal impairment (eGFR 15–29mL/min/1.73m²). Moderate or severe hepatic impairment (total bilirubin >1.5×ULN and any AST). Embryo-fetal toxicity. Advise females of reproductive potential and males (w. female partners) to use effective non-hormonal contraception during and for 1 week after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 1 week after the last dose).

Monitor for anemia, oxygen saturation prior to initiation and periodically during therapy. Withhold for hemoglobin <9g/dL or transfusion indicated until resolved; resume at reduced dose or permanently discontinue based on severity of anemia. For life-threatening anemia or when urgent intervention is indicated; withhold until resolved; resume at reduced dose or permanently discontinue. Consider withholding therapy for decreased oxygen saturation with exercise (eg, pulse oximeter <88% or P_aO₂ ≤55mmHg) until resolved, then resume at same or reduced dose. Withhold for decreased oxygen saturation at rest (eg, pulse oximeter <88% or P_aO₂ ≤55mmHg) or urgent intervention indicated until resolved; resume at reduced dose or discontinue based on severity of hypoxia. Permanently discontinue if life-threatening or recurrent symptomatic hypoxia occurs. Poor metabolizers (dual UGT2B17/CYP2C19): monitor closely. Severe renal impairment (eGFR 15–29mL/min/1.73m²). Moderate or severe hepatic impairment (total bilirubin >1.5×ULN and any AST). Embryo-fetal toxicity. Advise females of reproductive potential and males (w. female partners) to use effective non-hormonal contraception during and for 1 week after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 1 week after the last dose).